Surgical Endoscopy

, Volume 22, Issue 4, pp 967–973 | Cite as

Intravenous pantoprazole utilization in a level 1 trauma center

  • David A. Edelman
  • Krupa R. Patel
  • James G. Tyburski
  • Lisa G. Hall Zimmerman



In recent years there has been a rapid increase in the use of proton pump inhibitors. Our institution has recently had several shortages of IV pantoprazole, each lasting 7–10 days. The purpose of our study was to evaluate in-patient usage of IV pantoprazole. We hypothesized that hospitalized patients with upper gastrointestinal bleeding (GIB) or risk for stress ulcers inappropriately received IV pantoprazole based on current literature.


This was a retrospective study of 165 consecutive in-patients identified as receiving pantoprazole from December 2004 to March 2005. Only patients receiving IV pantoprazole were included (n = 78). Data collected included demographics, indication and dosing of pantoprazole, admitting team (surgery vs. medicine), and risk factors for stress ulcers.


Our study population had a mean age of 54 ± 17 years and 62% were male. Overall, 45% (35/78) of patients receiving IV pantoprazole had an appropriate indication, and 19% (15/78) received the correct dose. Of the 78 patients, 43 (55%) were treated with pantoprazole for stress ulcer prophylaxis (SUP), and 35 (45%) patients were treated for GIB. We found that none of the 43 patients treated for SUP had an appropriate indication for pantoprazole, but all of the patients with GIB (35) had an appropriate indication. Of the 35 patients treated for GIB with pantoprazole, only 40% (14/35) received the correct dose. In all cases of incorrect dosing, the patients were underdosed.


Pantoprazole is not being prescribed appropriately for stress ulcer prophylaxis in our patient population. Even in patients appropriately receiving pantoprazole the majority were prescribed an incorrect dose. Appropriate indications and dosing of pantoprazole could eliminate the shortages seen at our institution.


Pantoprazole Proton pump inhibitors Gastrointestinal bleeding Stress ulcer prophylaxis Drug shortage 


  1. 1.
    Pisegna JR (2002) Pharmacology of acid suppression in the hospital setting: Focus on proton pump inhibition. Crit Care Med 30:S356–361Google Scholar
  2. 2.
    Shuman RB, Schuster DP, Zuckerman GR (1987) Prophylactic therapy for stress ulcer bleeding: A reappraisal. Ann Intern Med 106:562–567PubMedGoogle Scholar
  3. 3.
    Cook D, Guyatt G, Marshall J, et al. (1998) A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian critical care trials group. N Engl JJ Med 338:791–797CrossRefGoogle Scholar
  4. 4.
    Devlin JW, Welage LS, Olsen KM (2005) Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics. Ann Pharmacother 39:1844–1851PubMedCrossRefGoogle Scholar
  5. 5.
    Daley RJ, Rebuck JA, Welage LS, et al. (2004) Prevention of stress ulceration: Current trends in critical care. Crit Care Med 32:2008–2013PubMedCrossRefGoogle Scholar
  6. 6.
    Conrad SA (2002) Acute upper gastrointestinal bleeding in critically ill patients: Causes and treatment modalities. Crit Care Med 30:S365–368PubMedCrossRefGoogle Scholar
  7. 7.
    Barkun A, Bardou M, Marshall JK (2003) Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 139:843–857PubMedGoogle Scholar
  8. 8.
    Levine JE, Leontiadis GI, Sharma VK, et al. (2002) Meta-analysis: The efficacy of intravenous h2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 16:1137–1142PubMedCrossRefGoogle Scholar
  9. 9.
    Leontiadis GI, McIntyre L, Sharma VK, et al. (2004) Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev: CD002094Google Scholar
  10. 10.
    Devlin JW, Welage LS, Olsen KM (2005) Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 39:1667–1677PubMedCrossRefGoogle Scholar
  11. 11.
    Kaplan GG, Bates D, McDonald D, et al. (2005) Inappropriate use of intravenous pantoprazole: Extent of the problem and successful solutions. Clin Gastroenterol Hepatol 3:1207–1214PubMedCrossRefGoogle Scholar
  12. 12.
    Guda NM, Noonan M, Kreiner MJ, et al. (2004) Use of intravenous proton pump inhibitors in community practice: An explanation for the shortage? Am J Gastroenterol 99:1233–1237PubMedCrossRefGoogle Scholar
  13. 13.
    Lee TJ, Fennerty MB, Howden CW (2004) Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 20:1241–1251PubMedCrossRefGoogle Scholar
  14. 14.
    Afif W, Alsulaiman R, Martel M, et al. (2007) Predictors of inappropriate utilization of intravenous proton pump inhibitors. Aliment Pharmacol Ther 25:609–615PubMedCrossRefGoogle Scholar
  15. 15.
    Naunton M, Peterson GM, Bleasel MD (2000) Overuse of proton pump inhibitors. J Clin Pharm Ther 25:333–340PubMedCrossRefGoogle Scholar
  16. 16.
    Leontiadis GI, Sharma VK, Howden CW (2006) Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane database syst rev: CD002094Google Scholar
  17. 17.
    Waldum HL, Brenna E, Kleveland PM, et al. (1993) Review article: The use of gastric acid-inhibitory drugs–physiological and pathophysiological considerations. Aliment Pharmacol Ther 7:589–596PubMedCrossRefGoogle Scholar
  18. 18.
    Selway SA (1990) Potential hazards of long-term acid suppression. Scand J Gastroenterol Suppl 178:85–92PubMedCrossRefGoogle Scholar
  19. 19.
    Lewis SJ, Franco S, Young G, et al. (1996) Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 10:557–561PubMedCrossRefGoogle Scholar
  20. 20.
    Verdu E, Viani F, Armstrong D, et al. (1994) Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and n-nitroso compounds. Gut 35:455–460PubMedCrossRefGoogle Scholar
  21. 21.
    Waldum HL, Arnestad JS, Brenna E, et al. (1996) Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39:649–653PubMedCrossRefGoogle Scholar
  22. 22.
    Wayman J, Hayes N, Raimes SA, et al. (2000) Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. Arch Fam Med 9:385–388PubMedCrossRefGoogle Scholar
  23. 23.
    Wayman J, Hayes N, Griffin SM (1998) The response of early gastric cancer to proton-pump inhibitors. N Engl JJ Med 338:1924–1925CrossRefGoogle Scholar
  24. 24.
    Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. (2002) Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 30:1118–1122PubMedCrossRefGoogle Scholar
  25. 25.
    Freston J, Chiu YL, Pan WJ, et al. (2001) Effects on 24-hour intragastric pH: A comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. Am J Gastroenterol 96:2058–2065PubMedCrossRefGoogle Scholar
  26. 26.
    Netzer P, Gaia C, Sandoz M, et al. (1999) Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric ph over 72 hours. Am J Gastroenterol 94:351–357PubMedGoogle Scholar
  27. 27.
    Morris JA, David B, Karlstadr R, et al. (2002) Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH > 4 compared with continuous infusion h2-receptor antagonist in intensive care unit patients. Crit Care Med 30:A117CrossRefGoogle Scholar
  28. 28.
    Navab F, Steingrub J (1995) Stress ulcer: Is routine prophylaxis necessary? Am J Gastroenterol 90:708–712PubMedGoogle Scholar
  29. 29.
    Gardner TB, Robertson DJ (2006) Stress ulcer prophylaxis in non-critically ill patients: Less may be more. Am J Gastroenterol 101:2206–2208PubMedCrossRefGoogle Scholar
  30. 30.
    Cook DJ, Fuller HD, Guyatt GH, et al. (1994) Risk factors for gastrointestinal bleeding in critically ill patients. Canadian critical care trials group. N Engl J Med 330:377–381PubMedCrossRefGoogle Scholar
  31. 31.
    Allen ME, Kopp BJ, Erstad BL (2004) Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm 61:588–596PubMedGoogle Scholar
  32. 32.
    Ashp therapeutic guidelines on stress ulcer prophylaxis. (1999) Ashp commission on therapeutics and approved by the ASHP board of directors on november 14, 1998. Am J Health Syst Pharm 56:347–379Google Scholar
  33. 33.
    Zink DA, Pohlman M, Barnes M, et al. (2005) Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Therap 21:1203–1209CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • David A. Edelman
    • 1
  • Krupa R. Patel
    • 1
  • James G. Tyburski
    • 1
  • Lisa G. Hall Zimmerman
    • 1
  1. 1.Surgery/Trauma Critical CareDetroit Receiving HospitalDetroitUS

Personalised recommendations